Altered expression of versican and hyaluronan in melanocytic tumors of dogs

American Journal of Veterinary Research

Volumn 68, Issue 12, 2007, Pages 1376-1385

  Docampo, María José ^a   Rabanal, Rosa M ^a   Miquel Serra, Laia ^a   Hernández, Daniel ^a   Domenzain, Clelia ^a   Bassols, Anna ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HYALURONIC ACID; HYALURONIDASE; VERSICAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CAPILLARY; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; CORRELATION ANALYSIS; DERMIS; DOG DISEASE; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; HAIR FOLLICLE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MELANOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIGENS, CD44; CELL LINE, TUMOR; DOG DISEASES; DOGS; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HYALURONIC ACID; ISOENZYMES; MELANOMA; VERSICANS;

CANIS FAMILIARIS;

EID: 37249014495     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.12.1376     Document Type: Article

References (55)

1. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol 2002;39:651-678.
2. Spangler WL, Kass PH. The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. Vet Pathol 2006;43:136-149.
3. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol Mech Dis 2006;1:119-150.
4. Labrousse AL, Ntayi C, Hornebeck W et al. Stromal reaction in cutaneous melanoma. Crit Rev Oncol Hematol 2004;49:269-275.
5. Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci 2000;57:276-289.
6. Seyfried NT, McVey GF, Almond A, et al. Expression and purification of functionally active hyaluronan-binding domains from human cartilage link protein, aggrecan and versican: formation of ternary complexes with defined hyaluronan oligosaccharides. J Biol Chem 2005;280:5435-5448.
7. Toole BP. Hyaluronan promotes the malignant phenotype. Glycobiology 2002;12:37R-42R.
8. Toole BP, Wight TN, Tammi MI. Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 2002;277:4593-4596.
9. Toole BP, Hascall VC. Hyaluronan and tumor growth. Am J Pathol 2002;161:745-747.
10. Zimmermann DR. Versican. In: Iozzo RV, ed. Proteoglycans: structure, biology and molecular interactions. New York: Marrel Dekker Inc, 2000;327-341.
11. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 2002;14:617-623.
12. LeBaron RG, Zimmermann DR, Ruoslahti E. Hyaluronate binding properties of versican. J Biol Chem 1992;267:10003-10010.
13. Knudson W. Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am J Pathol 1996;148:1721-1726.
14. Touab M, rumi-Uria M, Barranco C, et al. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi. Am J Clin Pathol 2003;119:587-593.
15. Touab M, Villena J, Barranco C, et al. Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 2002;160:549-557.
16. Serra M, Pastor J, Domenzain C, et al. Effect of transforming growth factor-beta1, insulin-like growth factor-I, and hepatocyte growth factor on proteoglycan production and regulation in canine melanoma cell lines. Am J Vet Res 2002;63:1151-1158.
17. Erdelyi I, Nieskens DH, van Dijk JE, et al. Immunohistochemical evaluation of versican, in relation to chondroitin sulphate, in canine mammary tumours. Histol Histopathol 2003;18:1067-1080.
18. Erdelyi I, van Asten AJ, van Dijk JE, et al. Expression of versican in relation to chondrogenesis-related extracellular matrix components in canine mammary tumors. Histochem Cell Biol 2005;124:139-149.
19. Mukaratirwa S, van Ederen AM, Gruys E, et al. Versican and hyaluronan expression in canine colonic adenomas and carcinomas: relation to malignancy and depth of tumour invasion. J Comp Pathol 2004;131:259-270.
20. Toole BP, Zoltan-Jones A, Misra S, et al. Hyaluronan: a critical component of epithelial-mesenchymal and epithelial-carcinoma transitions. Cells Tissues Organs 2005;179:66-72.
21. Karjalainen JM, Tammi RH, Tammi MI, et al. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol 2000;157:957-965.
22. Bajorath J. Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins 2000;39:103-111.
23. Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004;35:211-231.
24. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002;277:4589-4592.
25. Li L, Asteriou T, Bernert B, et al. Growth factor regulation of hyaluronan synthesis and degradation in human dermal fibroblasts: importance of hyaluronan for the mitogenic response of PDGF-BB. Biochem J 2007;404:327-336.
26. Zimmermann DR, Dours-Zimmermann MT, Schubert M, et al. Versican is expressed in the proliferating zone in the epidermis and in association with the elastic network of the dermis. J Cell Biol 1994;124:817-825.
27. Serra M, Rabanal RM, Miquel L, et al. Differential expression of CD44 in canine melanocytic tumours. J Comp Pathol 2004;130:171-180.
28. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004;4:528-539.
29. Adamia S, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:3-14.
30. Brinck J, Heldin P. Expression of recombinant hyaluronan synthase (HAS) isoforms in CHO cells reduces cell migration and cell surface CD44. Exp Cell Res 1999;252:342-351.
31. Goldschmidt MH, Dustan RW, Stannard AA, et al. Histological classification of epithelial and melanocytic tumors of the skin of domestic animals. In: Shulmann FY, ed. WHO international histological classification of tumors of domestic animals. 2nd ed. Washington, DC: Armed Forces Institute of Pathology, 1998;38-41.
32. Head KW, Cullen JM, Dubielzig RR, et al. Histological classification of tumors of the alimentary system of domestic animals. In: Shulmann FY, ed. WHO international histological classification of tumors of domestic animals. 2nd ed. Washington, DC: Armed Forces Institute of Pathology, 2003;33-35.
33. Alldinger S, Baumgartner W, Kremmer E, et al. Characterization of a canine CD44 specific monoclonal antibody. Zentralbl Veterinarmed [A] 1999;46:19-32.
34. Auvinen P, Tammi R, Tammi M, et al. Expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology 2005;47:420-428.
35. Wolfe LG, Oliver JL, Smith BB, et al. Biologic characterization of canine melanoma cell lines. Am J Vet Res 1987;48:1642-1648.
36. Zimmermann DR, Dours-Zimmermann MT, Schubert M, et al. Versican is expressed in the proliferating zone in the epidermis and in association with the elastic network of the dermis. J Cell Biol 1994;124:817-825.
37. Bode-Lesniewska B, Dours-Zimmermann MT, Odermatt BF, et al. Distribution of the large aggregating proteoglycan versican in adult human tissues. J Histochem Cytochem 1996;44:303-312.
38. du Cros DL, LeBaron RG, Couchman JR. Association of versican with dermal matrices and its potential role in hair follicle development and cycling. J Invest Dermatol 1995;105:426-431.
39. Kishimoto J, Ehama R, Wu L, et al. Selective activation of the versican promoter by epithelial- mesenchymal interactions during hair follicle development. Proc Natl Acad Sci U S A 1999;96:7336-7341.
40. Soma T, Tajima M, Kishimoto J. Hair cycle-specific expression of versican in human hair follicles. J Dermatol Sci 2005;39:147-154.
41. du Cros DL, LeBaron RG, Couchman JR. Association of versican with dermal matrices and its potential role in hair follicle development and cycling. J Invest Dermatol 1995;105:426-431.
42. Tammi R, Ripellino JA, Margolis RU, et al. Localization of epidermal hyaluronic acid using the hyaluronate binding region of cartilage proteoglycan as a specific probe. J Invest Dermatol 1988;90:412-414.
43. Tammi R, Tammi M, Hakkinen L, et al. Histochemical localization of hyaluronate in human oral epithelium using a specific hyaluronate-binding probe. Arch Oral Biol 1990;35:219-224.
44. Wang C, Tammi M, Tammi R. Distribution of hyaluronan and its CD44 receptor in the epithelia of human skin appendages. Histochemistry 1992;98:105-112.
45. Serra M, Brazis P, Puigdemont A, et al. Development and characterization of a canine skin equivalent. Exp Dermatol 2007;16:135-142.
46. Mukaratirwa S, van Ederen AM, Gruys E, et al. Versican and hyaluronan expression in canine colonic adenomas and carcinomas: relation to malignancy and depth of tumour invasion. J Comp Pathol 2004;131:259-270.
47. Koyama H, Hibi T, Isogai Z, et al. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Anti Pathol 2007; 170:1086-1099.
48. Ichikawa T, Itano, N, Sawai T, et al. Increased synthesis of hyaluronate enhances motility of human melanoma cells. J Invest Dermatol 1999;113:935-939.
49. Mummert ME, Mummert DI, Ellinger L, et al. Functional roles of hyaluronan in B16-F10 melanoma growth and experimental metastasis in mice. Mol Cancer Ther 2003;2:295-300.
50. Udabage L, Brownlee GR, Nilsson SK, et al. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 2005;310:205-217.
51. Stern R. Devising a pathway for hyaluronan catabolism: are we there yet? Glycobiology 2003;13:105R-115R.
52. Stern R. Hyaluronan metabolism: a major paradox in cancer biology. Pathol Biol (Paris) 2005;53:372-382.
53. Simpson MA, Reiland J, Burger SR, et al. Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells. J Biol Chem 2001;276:17949-17957.
54. Yamada Y, Itano N, Narimatsu H, et al. Elevated transcript level of hyaluronan synthase 1 gene correlates with poor prognosis of human colon cancer. Clin Exp Metastasis 2004;21:57-63.
55. Liu Z, Dobra K, Hauzenberger D, et al. Expression of hyaluronan synthases and hyaluronan in malignant mesothelioma cells. Anticancer Res 2004;24:599-603.